Home/Filings/4/0000899243-18-000454
4//SEC Filing

Barrowcliffe Susan E. 4

Accession 0000899243-18-000454

CIK 0001631650other

Filed

Jan 3, 7:00 PM ET

Accepted

Jan 4, 4:05 PM ET

Size

20.0 KB

Accession

0000899243-18-000454

Insider Transaction Report

Form 4
Period: 2018-01-02
Barrowcliffe Susan E.
General Manager, Europe
Transactions
  • Sale

    Common Stock, $0.0001 par value

    2018-01-02$37.78/sh599$22,62950,000 total
  • Sale

    Common Stock, $0.0001 par value

    2018-01-02$37.12/sh24,401$905,81150,599 total
  • Sale

    Common Stock, $0.0001 par value

    2018-01-02$37.13/sh24,700$917,02225,300 total
  • Sale

    Common Stock, $0.0001 par value

    2018-01-02$37.12/sh24,400$905,716600 total
  • Exercise/Conversion

    Common Stock, $0.0001 par value

    2018-01-02$3.02/sh+75,000$226,65075,000 total
  • Sale

    Common Stock, $0.0001 par value

    2018-01-02$37.86/sh300$11,35925,000 total
  • Sale

    Common Stock, $0.0001 par value

    2018-01-02$37.75/sh600$22,6520 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2018-01-0275,00093,400 total
    Exercise: $3.02Exp: 2025-05-13Common Stock (75,000 underlying)
Footnotes (8)
  • [F1]The sales reported in the Form 4 were effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
  • [F2]The transaction was executed in multiple trades in prices ranging from $36.58 to $37.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F3]The transaction was executed in multiple trades in prices ranging from $37.70 to $37.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F4]The transaction was executed in multiple trades in prices ranging from $36.60 to $37.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F5]The transaction was executed in multiple trades in prices ranging from $37.85 to $37.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F6]The transaction was executed in multiple trades in prices ranging from $36.55 to $37.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F7]The transaction was executed in multiple trades in prices ranging from $37.65 to $37.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  • [F8]The option is immediately exercisable in full or in part. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from May 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Issuer

Aimmune Therapeutics, Inc.

CIK 0001631650

Entity typeother

Related Parties

1
  • filerCIK 0001664251

Filing Metadata

Form type
4
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 4:05 PM ET
Size
20.0 KB